Drug Pipeline Activity: Hepatitis C

We will see a new wave of oral antiviral hepatitis C medicines hitting the market towards the end of this year and the beginning of next year, noted Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

This video was shot at the 2013 Academy of Managed Care Pharmacy Nexus meeting in San Antonio, Texas.

BONUS:

For more information about HCV therapies, read this article on simeprevir and check out the below graph on sofosbuvir SVR rates: